Joseph Manhede was named Principal Accounting Officer of Rocket Pharmaceuticals, Inc., effective July 8, 2026. As of November 6, 2026, Rocket Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 30, 2026, naming 1 appointment (Form 8-K, June 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Rocket Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Rocket Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-30. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Rocket Pharmaceuticals, Inc. files it.
Also on the record for Rocket Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G/A, by Vanguard Portfolio Management | 1.33% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.35% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Maverick Capital, Ltd. | 2.3% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | 7.89% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Maverick Capital, Ltd. | 7.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Rocket Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Rocket Pharmaceuticals, Inc. and the records around it.
Rocket Pharmaceuticals, Inc. elsewhere on the record
Companies that share a holder
- Maverick Capital, Ltd. also filed stake reports on 5 other companies: Infleqtion, Inc. (May 2026), Invivyd, Inc. (Feb 2026), Peabody Energy Corporation (Feb 2026)
- Vanguard Portfolio Management also filed stake reports on 941 other companies: Newmark Group Inc (Nov 2026), A10 Networks Inc (Oct 2026), ADT Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Rocket Pharmaceuticals, Inc.
Get an email when Rocket Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Rocket Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Rocket Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Rocket Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-30 | In | Principal Accounting Officer | 2026-07-08 | 8-K, 2026-06-30 |
Who leads Rocket Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Principal Accounting Officer: Joseph Manhede, appointed, effective 2026-07-08 (filed 2026-06-30).
New leaders reset buying decisions — get the Full Report on Rocket Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Principal Accounting Officer at Rocket Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Principal Accounting Officer at Rocket Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: Joseph Manhede, Principal Accounting Officer, effective 2026-07-08
On June 30, 2026, Joseph Manhede, the Company's Associate Vice President, Corporate Controller, was appointed as the Company's Principal Accounting Officer, effective July 8, 2026.
- On June 24, 2026, John Militello informed Rocket Pharmaceuticals, Inc. (the "Company" or "Rocket") of his resignation as VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer, effective July 7, 2026, to pursue other opportunities.
- Mr. Manhede, age 48, has served as the Company's Associate Vice President, Corporate Controller since April 2026.
- Prior to Rocket, Mr. Manhede was the Vice President and Financial Controller for Outlook Therapeutics, a clinical-stage biopharmaceutical company, where he was responsible for leading accounting and finance functions, including financial reporting, SEC compliance, internal controls, budgeting, and strategic financial planning, as well as supporting financing transactions and corporate governance initiatives.
- Prior to his time at Outlook, Mr. Manhede held senior finance and accounting positions at Amneal Pharmaceuticals, Unilife Corporation, and Celator Pharmaceuticals, Inc., where he served as Corporate Controller and played a key role in financial reporting, IPO readiness, SOX compliance, and acquisition integration.
- He began his career at Deloitte, where he served as an Audit Manager.
- Mr. Manhede is a Certified Public Accountant (CPA) and holds a Master of Business Administration from Holy Family University.
Tools for this story
Each opens in a new tab, filled in for Rocket Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.